01 1Symdeko
02 2Symdeko
03 3Symdeko/Symkevi
04 2Trikafta
05 3Trikafta/Kaftrio
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2019 Revenue in Millions : 1,418
2018 Revenue in Millions : 769
Growth (%) : 84
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2019 Revenue in Millions : 420
2018 Revenue in Millions : 0
Growth (%) : New launch
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 3,864
2019 Revenue in Millions : 420
Growth (%) : 820
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 629
2019 Revenue in Millions : 1,418
Growth (%) : -56
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 5,697
2020 Revenue in Millions : 3,864
Growth (%) : 32
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 420
2020 Revenue in Millions : 629
Growth (%) : -50
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 7,687
2021 Revenue in Millions : 5,697
Growth (%) : 35
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 180
2021 Revenue in Millions : 420
Growth (%) : -57
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 123
2022 Revenue in Millions : 180
Growth (%) : -46
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 8,945
2022 Revenue in Millions : 7,687
Growth (%) : 14
LOOKING FOR A SUPPLIER?
